Drug-resistant Bacteria should fear Discuva’s antimicrobials

01/07/2016 - 2 minutes

Duty calls on the Island of Queen Elizabeth II…. What will be the future of Biotech in the United Kingdom and in Europe?

Last week we did a review to catch up with all the details of #Brexit and this is why we decided to head up to Cambridge, one of the major biotech and research centers in the United Kingdom and visit Discuva, our Biotech of the Week.


City: Cambridge (UK)

Founded: 2009

Employees: 50

Financial Data: N/A

CEO: David Williams


Mission: Discuva wants to create the next generation of targeted antimicrobials. Its approach to fighting a future antimicrobial resistance crisis has already attracted the attention of Roche. The Swiss Giant struck a collaboration that could worth up to $175M per approved product.

Regarding technology, Discuva relies on two platforms. SATIN  discovers compounds that also target genes associated with resistance,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member